These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37574751)

  • 1. Reevaluation of bromodomain ligands targeting BAZ2A.
    Cazzanelli G; Vedove AD; Parolin E; D'Agostino VG; Unzue A; Nevado C; Caflisch A; Lolli G
    Protein Sci; 2023 Sep; 32(9):e4752. PubMed ID: 37574751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B.
    Chen P; Chaikuad A; Bamborough P; Bantscheff M; Bountra C; Chung CW; Fedorov O; Grandi P; Jung D; Lesniak R; Lindon M; Müller S; Philpott M; Prinjha R; Rogers C; Selenski C; Tallant C; Werner T; Willson TM; Knapp S; Drewry DH
    J Med Chem; 2016 Feb; 59(4):1410-24. PubMed ID: 25799074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Analysis of Small-Molecule Binding to the BAZ2A and BAZ2B Bromodomains.
    Dalle Vedove A; Spiliotopoulos D; D'Agostino VG; Marchand JR; Unzue A; Nevado C; Lolli G; Caflisch A
    ChemMedChem; 2018 Jul; 13(14):1479-1487. PubMed ID: 29770599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure enabled design of BAZ2-ICR, a chemical probe targeting the bromodomains of BAZ2A and BAZ2B.
    Drouin L; McGrath S; Vidler LR; Chaikuad A; Monteiro O; Tallant C; Philpott M; Rogers C; Fedorov O; Liu M; Akhtar W; Hayes A; Raynaud F; Müller S; Knapp S; Hoelder S
    J Med Chem; 2015 Mar; 58(5):2553-9. PubMed ID: 25719566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer.
    Bevill SM; Olivares-Quintero JF; Sciaky N; Golitz BT; Singh D; Beltran AS; Rashid NU; Stuhlmiller TJ; Hale A; Moorman NJ; Santos CM; Angus SP; Zawistowski JS; Johnson GL
    Mol Cancer Res; 2019 Jul; 17(7):1503-1518. PubMed ID: 31000582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of BAZ2A bromodomain ligands.
    Spiliotopoulos D; Wamhoff EC; Lolli G; Rademacher C; Caflisch A
    Eur J Med Chem; 2017 Oct; 139():564-572. PubMed ID: 28837921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GSK2801 Reverses Paclitaxel Resistance in Anaplastic Thyroid Cancer Cell Lines through MYCN Downregulation.
    Molteni E; Baldan F; Damante G; Allegri L
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo CRISPR screening identifies BAZ2 chromatin remodelers as druggable regulators of mammalian liver regeneration.
    Jia Y; Li L; Lin YH; Gopal P; Shen S; Zhou K; Yu X; Sharma T; Zhang Y; Siegwart DJ; Ready JM; Zhu H
    Cell Stem Cell; 2022 Mar; 29(3):372-385.e8. PubMed ID: 35090595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a BAZ2A Bromodomain Hit Compound by Fragment Joining.
    Dalle Vedove A; Cazzanelli G; Corsi J; Sedykh M; D'Agostino VG; Caflisch A; Lolli G
    ACS Bio Med Chem Au; 2021 Dec; 1(1):5-10. PubMed ID: 36147311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a BAZ2A-Bromodomain Hit Compound by Fragment Growing.
    Dalle Vedove A; Cazzanelli G; Batiste L; Marchand JR; Spiliotopoulos D; Corsi J; D'Agostino VG; Caflisch A; Lolli G
    ACS Med Chem Lett; 2022 Sep; 13(9):1434-1443. PubMed ID: 36105334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of chemical probes for the bromodomains of BRD7 and BRD9.
    Clark PG; Dixon DJ; Brennan PE
    Drug Discov Today Technol; 2016 Mar; 19():73-80. PubMed ID: 27769361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational Design and Development of Selective BRD7 Bromodomain Inhibitors and Their Activity in Prostate Cancer.
    Ordonez-Rubiano SC; Maschinot CA; Wang S; Sood S; Baracaldo-Lancheros LF; Strohmier BP; McQuade AJ; Smith BC; Dykhuizen EC
    J Med Chem; 2023 Aug; 66(16):11250-11270. PubMed ID: 37552884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BAZ2A-mediated repression via H3K14ac-marked enhancers promotes prostate cancer stem cells.
    Peña-Hernández R; Aprigliano R; Carina Frommel S; Pietrzak K; Steiger S; Roganowicz M; Lerra L; Bizzarro J; Santoro R
    EMBO Rep; 2021 Nov; 22(11):e53014. PubMed ID: 34403195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer.
    Zou LJ; Xiang QP; Xue XQ; Zhang C; Li CC; Wang C; Li Q; Wang R; Wu S; Zhou YL; Zhang Y; Xu Y
    Acta Pharmacol Sin; 2019 Nov; 40(11):1436-1447. PubMed ID: 31097763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding Selectivity of Inhibitors toward Bromodomains BAZ2A and BAZ2B Uncovered by Multiple Short Molecular Dynamics Simulations and MM-GBSA Calculations.
    Wang L; Wang Y; Yang Z; Xu S; Li H
    ACS Omega; 2021 May; 6(18):12036-12049. PubMed ID: 34056358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological function and histone recognition of family IV bromodomain-containing proteins.
    Lloyd JT; Glass KC
    J Cell Physiol; 2018 Mar; 233(3):1877-1886. PubMed ID: 28500727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural Basis of Inhibitor Selectivity in the BRD7/9 Subfamily of Bromodomains.
    Karim RM; Chan A; Zhu JY; Schönbrunn E
    J Med Chem; 2020 Mar; 63(6):3227-3237. PubMed ID: 32091206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recognition of hyperacetylated N-terminus of H2AZ by TbBDF2 from
    Yang X; Wu X; Zhang J; Zhang X; Xu C; Liao S; Tu X
    Biochem J; 2017 Nov; 474(22):3817-3830. PubMed ID: 29025975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective recognition of acetylated histones by bromodomains in transcriptional co-activators.
    Hassan AH; Awad S; Al-Natour Z; Othman S; Mustafa F; Rizvi TA
    Biochem J; 2007 Feb; 402(1):125-33. PubMed ID: 17049045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition.
    Theodoulou NH; Bamborough P; Bannister AJ; Becher I; Bit RA; Che KH; Chung CW; Dittmann A; Drewes G; Drewry DH; Gordon L; Grandi P; Leveridge M; Lindon M; Michon AM; Molnar J; Robson SC; Tomkinson NC; Kouzarides T; Prinjha RK; Humphreys PG
    J Med Chem; 2016 Feb; 59(4):1425-39. PubMed ID: 25856009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.